Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor
management reduces the likelihood of late-stage diabetic complications. Guidelines …

Aims To evaluate the efficacy and safety of oral semaglutide versus comparators by patient
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are recommended for glycaemic
management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP …

Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …

To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …

Oral semaglutide (Rybelsus®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-
1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral …

Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Aim To evaluate the impact of relevant patient‐level characteristics on the efficacy and safety
of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials and …